Tinidazole
- Atc Codes:J01XD02#P01AB02
- CAS Codes:19387-91-8
- PHARMGKB ID:19387-91-8
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Fasigyn; Bulgaria: Tinidazol; Cyprus: Tinirem; France: Fasigyne; Greece: Fasigyn; Hungary: Tinidazol; Italy: Fasigin, Trimonase; Latvia: Tiniba, Tinidazol; Lithuania: Tinidazol; Poland: Tinidazolum; Portugal: Fasigyn; Romania: Fasigyn, Tinizol, Tiprogyn; Spain: Tricolam; Sweden: Fasigyn; UK: Fasigyn.
North America
USA: Tindamax.
Latin America
Argentina: Ladylen Duo; Brazil: Amplium, Facyl, Fasigyn, Ginosutin, Pletil, Tinidazol, Tinoral; Mexico: Ametricid, Estovyn T, Fasigyn, Induken, Tinidazol, Trinigyn, Triseptil.
Asia
Japan: Haisigyn.
Drug combinations
Tinidazole and Fluconazole
Tinidazole and Mebendazole
Chemistry
Tinidazole: C~8~H~13~N~3~O~4~S. Mw: 247.27. (1) 1H-Imidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-; (2) 1-[2-(Ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole. CAS-19387-91-8 (1970).
Pharmacologic Category
Miscellanous Antiprotozoals. Amebicide. Nitroimidazole. (ATC-Code: J01XD02; P01AB02).
Mechanism of action
After diffusing into organism, it is proposed that tinidazole causes cytotoxicity by damaging DNA and preventing further DNA synthesis.
Therapeutic use
Treatment of trichomoniasis caused by T. Vaginalis. Treatment of giardiasis caused by G. duodenalis (G. lamblia). Treatment of intestinal amebiasis and amebic liver abscess caused by E. Histolytica. Treatment of bacterial vaginosis caused by Bacteroides spp, Gardnerella vaginalis, and Prevotella spp in nonpregnant females.
Pregnancy and lactiation implications
Crosses placenta and enters fetal circulation. Teratogenic effects not observed in animal studies. Should not be used during pregnancy for treatment of bacterial vaginosis. Use during 1^st^ trimester contraindicated. Use during 2^nd^ and 3^rd^ trimesters only if clearly needed. Contraindicated in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to tinidazole, nitroimidazole derivatives (including metronidazole), or any component of the formulation. Pregnancy (first trimester). Breast-feeding.
Warnings and precautions
Carcinogenicity observed with another nitroimidazole derivative (metronidazole) in animal studies. Seizures and peripheral neuropathy reported with tinidazole and other nitroimidazole derivatives. Use with caution in CNS diseases. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea, pseudomembranous colitis, and/or vaginal candidiasis. When used for amebiasis, not indicated for treatment of asymptomatic cyst passage. Use with caution in current or history of blood dyscrasias, and in current or history of hepatic impairment.